Better Therapeutics, Inc. (NASDAQ:BTTX) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET

Company Participants

Mark Heinen - Chief Financial Officer

Frank Karbe - President and CEO

Diane Gomez-Thinnes - Chief Commercial Officer

Mark Berman - Chief Medical Officer

Conference Call Participants

Thomas Flaten - Lake Street Capital Markets

Rahul Rakhit - LifeSci Capital

Operator

Good day and thank you for standing by. Welcome to the Better Therapeutics' Third Quarter 2023 Business Update Call. At this time all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Mark Heinen, Chief Executive Officer. Please go ahead.

Mark Heinen

Thank you, operator. Good morning, everyone, and welcome to the Better Therapeutics conference call. Our press release was issued this morning and can be found in the Investors section of our corporate website, bettertx.com.

Joining me on the call today is Frank Karbe, our President and Chief Executive Officer; Dr. Mark Berman, our Chief Medical Officer; and Diane Gomez-Thinnes, our Chief Commercial Officer. During today's call, we will provide a business update and a financial overview of the third quarter of 2023. A Q&A session will follow our prepared remarks.

Before we begin, I'd like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans, and expectations that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events and results may differ materially from those expressed or implied by any forward-looking statement.

With that, I'll pass the call over Frank. Frank?

Frank Karbe

Thank you, Mark, and good morning, everyone. Thanks for joining us on the call today. I am delighted to start this call with the exciting news that AspyreRx is now available for commercial use. We've started receiving prescriptions and have patients on active treatment.

Over the past quarter, we have made substantial progress following the news in July that the FDA authorized AspyreRx as a Class 2 medical device, indicated to treat adults with Type 2 diabetes.

Our team completed development work to prepare the product for commercial release, established the necessary organizational infrastructure to launch a regulated prescription product into the market, and continued engaging payers to obtain coverage.